Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

NCT04911959 PHASE1, PHASE2 UNKNOWN

single-center clinical trial studies have verified the safety and effectiveness of transcatheter arterial chemoembolization (TACE) combined with lenvatinib in preventing postoperative recurrence of microvascular invasion (MVI) positive HCC patients. Explore a new clinical first-line treatment plan for patients with liver cancer microvascular invasion after surgery.

Details

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	PHASE1, PHASE2
Status	UNKNOWN
Enrolment	50
Start date	Fri Jul 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Jun 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatocellular Carcinoma
• Lenvatinib

Interventions

• Lenvatinib
• TACE

Countries

China